ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0486

Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Abstract Number: 2527

Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Abstract Number: 1091

Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Abstract Number: 1538

Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Abstract Number: 0332

Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1939

Salivary Gland Ultrasounds Can Be Read by General Radiologists: A Review Of 4 Years of Reports from an Urban Academic Radiology Department
Abstract Number: 0870

Same Model, Different Results: Vendor and Microbiome Influence Reproducibility in Collagen Induced Arthritis
Abstract Number: 1853

SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Abstract Number: 0202

Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Abstract Number: 0064

Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Abstract Number: 2123

Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia
Abstract Number: 1061

Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Abstract Number: 1943

Searching for subclinical synovitis and erosions in seropositive palindromic rheumatism: the added value of the ultrasonographic study of feet
Abstract Number: 1903

Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
Abstract Number: 1026

Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].